Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 8/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141500 | 0.85 | KDM4E (0.58) | KDM4EMAPTTHRBPDE10AGPR119 | |
| SCHEMBL12622802 | 0.85 | RBP4 (0.50) | KDM4ECALCRLRBP4 | |
| SCHEMBL5745535 | 0.82 | RBP4 (0.51) | KDM4ECALCRLRBP4 | |
| SCHEMBL29872305 | 0.81 | RBP4 (0.50) | KDM4ECALCRLRBP4 | |
| SCHEMBL30851884 | 0.80 | KDM4E (0.49) | KDM4EMAPTTHRBGPR119HPGDS | |
| SCHEMBL30852213 | 0.79 | PDE10A (0.54) | KDM4EMAPTTHRBPDE10AGPR119 | |
| SCHEMBL23564700 | 0.79 | AKR1C3 (0.45) | CALCRLRBP4 | |
| SCHEMBL13313599 | 0.78 | HRH4 (0.49) | CALCRLRBP4VCP | |
| SCHEMBL30851642 | 0.78 | KDM4E (0.49) | KDM4EMAPTTHRBPDE10AGPR119 | |
| SCHEMBL992227 | 0.77 | HTR2B (0.59) | MAPTPDE10AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | CALCRL, CALCA, CALCB | KDM4E 2986/4885MAPT 2748/4885THRB 918/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | KDM4E 2986/4885MAPT 2748/4885THRB 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.